Kostas Biliouris
Stock Analyst at BMO Capital
(0.90)
# 3,618
Out of 4,670 analysts
47
Total ratings
25%
Success rate
-13.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $17.04 | +105.40% | 6 | Sep 16, 2024 | |
| MGX Metagenomi | Maintains: Outperform | $22 → $17 | $1.89 | +799.47% | 2 | Aug 15, 2024 | |
| IONS Ionis Pharmaceuticals | Downgrades: Market Perform | $67 → $60 | $34.01 | +76.42% | 1 | Aug 2, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $63 → $40 | $7.79 | +413.48% | 4 | Jul 18, 2024 | |
| LEGN Legend Biotech | Maintains: Outperform | $90 | $40.94 | +119.83% | 3 | Jul 3, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $234 | $244.89 | -4.45% | 4 | Jun 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $170 → $200 | $114.23 | +75.09% | 4 | Jun 24, 2024 | |
| KRRO Korro Bio | Maintains: Outperform | $120 | $52.31 | +129.40% | 3 | May 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $62 → $70 | $14.30 | +389.51% | 5 | May 10, 2024 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 | $25.05 | +127.54% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $23.42 | +57.98% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $7.01 | +855.78% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $64.26 | +55.62% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.20 | +493.75% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $210 → $120 | $7.26 | +1,552.89% | 2 | Mar 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $4.85 | +1,178.35% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $47.88 | +104.68% | 1 | Jun 17, 2022 |
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $17.04
Upside: +105.40%
Metagenomi
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.89
Upside: +799.47%
Ionis Pharmaceuticals
Aug 2, 2024
Downgrades: Market Perform
Price Target: $67 → $60
Current: $34.01
Upside: +76.42%
4D Molecular Therapeutics
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $7.79
Upside: +413.48%
Legend Biotech
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $40.94
Upside: +119.83%
Alnylam Pharmaceuticals
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $244.89
Upside: -4.45%
Sarepta Therapeutics
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $114.23
Upside: +75.09%
Korro Bio
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $52.31
Upside: +129.40%
Intellia Therapeutics
May 10, 2024
Maintains: Outperform
Price Target: $62 → $70
Current: $14.30
Upside: +389.51%
Beam Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $25.05
Upside: +127.54%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $23.42
Upside: +57.98%
Jan 31, 2024
Initiates: Outperform
Price Target: $67
Current: $7.01
Upside: +855.78%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $64.26
Upside: +55.62%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.20
Upside: +493.75%
Mar 14, 2023
Downgrades: Market Perform
Price Target: $210 → $120
Current: $7.26
Upside: +1,552.89%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $4.85
Upside: +1,178.35%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $47.88
Upside: +104.68%